One-Shot antibody shields kids from malaria in landmark trial
NCT ID NCT05400655
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a single injection of an antibody called L9LS in healthy Kenyan children aged 5 months to 10 years. The goal was to see if it safely protects against malaria infection caused by the Plasmodium falciparum parasite. The trial involved 912 children and was completed, focusing on safety and how well the antibody works in a high-transmission area.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kenya Medical Research Institute (KEMRI) Center for Global Health Research (CGHR)
Kisumu, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth